GlassScriptPhysician profile
Kamee D Witts
NPI 1083319214
$2,237.31
in general payments reported to CMS, 2019-2025
13 companies · $891 in 2025
The $891 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $511 · 2024: $835 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213 · Education: $24.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.01 |
| Education | $24.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $576.60 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $530.88 | 2023-2025 | Spravato, Invega, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $208.14 | 2024-2025 | Fanapt |
| Abbvie INC. | $179.16 | 2025 | |
| Axsome Therapeutics, INC. | $145.80 | 2023-2025 | Auvelity |
| Janssen Scientific Affairs, LLC | $135.45 | 2023 | Spravato |
| Alkermes, INC. | $115.55 | 2023-2025 | Lybalvi, Vivitrol, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $101.32 | 2025 | Austedo Xr |
| Neuronetics, INC. | $93.19 | 2024 | Neurostar Tms Therapy System |
| Almatica Pharma LLC | $85.60 | 2024-2025 | Loreev Xr |
| Indivior INC. | $37.65 | 2023 | Sublocade |
| Noven Therapeutics, LLC | $14.05 | 2024 | Xelstrym |
| Luye Pharma (USA) LTD. | $13.92 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamee Witts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.